Printer Friendly

GV MEDICAL BEGINS CLINICAL TRIALS OF LASER DIAGNOSTIC SYSTEM

 GV MEDICAL BEGINS CLINICAL TRIALS OF LASER DIAGNOSTIC SYSTEM
 MINNEAPOLIS, Oct. 13 /PRNewswire/ -- GV Medical, Inc., (NASDAQ: GVMI) today announced an agreement with the Cleveland Clinic Foundation for clinical trials of a new diagnostic system designed to use laser-induced fluorescence to identify and characterize vascular disease.
 The company said the first phase of the study will involve 30 patients who are undergoing interventional atherectomy procedures in which diseased vascular tissue will be excised. An optical fiber will be introduced percutaneously and advanced to the site of the lesion, and a low-power laser will be used to illuminate the area to obtain fluorescence spectra. This spectral data will be compared with histological findings, and with angiographic, angioscopic and ultrasound images to assess the degree of correlation.
 Daryl F. Yurek, chairman and chief executive officer of GV Medical, said first use of the system was last week. Initially, the system will be used in peripheral vessels to help the doctors become familiar with its operation, Yurek said, with tests progressing to include the coronary arteries within a few weeks.
 Principal investigator for the Cleveland Clinic Foundation is Dr. Paul N. Casale of the Clinic's Department of Cardiology.
 GV Medical is based in Minneapolis. The laser diagnostic system is currently the main focus of the company's development efforts. A laser system which combines both diagnostic and therapeutic functions is also under development. The company's first laser system, known as LASTAC(R), has been approved for ablating plaque in peripheral arteries and is awaiting approval from the U.S. Food and Drug Administration for use in coronary arteries.
 -0- 10/13/92
 /CONTACT: Curt Swenson of Swenson Falker Eilertsen Inc., 612-371-0000, for GV Medical; or Tom Ahmann of GV Medical, Inc., 612-559-4000/
 (GVMI) CO: GV Medical, Inc. ST: Minnesota IN: MTC SU:


AL -- MN002 -- 9138 10/13/92 09:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1992
Words:307
Previous Article:IRS ISSUES CAUTION TO CONSUMERS REGARDING FLORIDA-BASED COMPANY
Next Article:L.A. GEAR REPORTS FINANCIAL RESULTS FOR THIRD QUARTER
Topics:


Related Articles
GV MEDICAL SELLS 4 MILLION SHARES OF COMMON STOCK
GV MEDICAL REPORTS 1991 RESULTS
GV MEDICAL REPORTS FIRST QUARTER RESULTS
GV MEDICAL AIMS TO DEVELOP DIAGNOSTIC SYSTEM AS STAND-ALONE PRODUCT; ANNOUNCES GRABEK RESIGNATION
CLEVELAND CLINIC DOCTORS REPORT THAT GV MEDICAL DEVICE SUCCESSFULLY IDENTIFIES TISSUE TYPES
GV MEDICAL ADOPTS NEW NAME: SPECTRASCIENCE
SPECTRASCIENCE REPORTS THIRD QUARTER RESULTS
COMPANY WILL RESUME CLINICAL TRIALS AS A RESULT OF PRODUCT ENHANCEMENTS; PRODUCT COMMERCIALIZATION ANTICIPATED IN 1994; DIRECTOR RESIGNS
IMAGING DIAGNOSTIC SYSTEMS RECEIVES ACCEPTANCE FROM FDA TO BEGIN CLINICAL TRIALS OF BREAST SCREENING UNDER IDE PROGRAM
Imaging Diagnostic Systems, Inc. Receives $15 Million Equity Line Of Credit

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters